Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Psychopharmacology (Berl). 2020 Jul;237(7):2201-2212. doi: 10.1007/s00213-020-05530-y. Epub 2020 May 8.
Synaptic neurotransmission with dopamine (DA), norepinephrine (NE), and serotonin (5-HT) is terminated primarily by reuptake into presynaptic terminals via the DA, NE, and 5-HT transporters (DAT/NET/SERT, respectively). Monoamine transporter inhibitors constitute one class of drugs used to treat both depression and pain, and therapeutic effects by these compounds often require repeated treatment for days or weeks.
The present study compared antinociceptive effects produced by repeated treatment with monoamine transporter inhibitors in a preclinical assay of pain-related depression of positively reinforced operant responding.
Adult Sprague-Dawley rats equipped with microelectrodes targeting a brain-reward area responded for pulses of electrical brain stimulation in an intracranial self-stimulation (ICSS) procedure. Intraperitoneal injection of dilute lactic acid served as a noxious stimulus that repeatedly depressed ICSS and also produced weight loss during 7 days of repeated acid administration.
Acid-induced depression of both ICSS and body weight were completely blocked by repeated pretreatment with the nonsteroidal anti-inflammatory drug ketorolac. The DAT-selective inhibitor bupropion also fully blocked acid-induced ICSS depression and weight loss throughout all 7 days of treatment. The NET-selective inhibitor nortriptyline and the SERT-selective inhibitor citalopram were generally less effective, but both drugs blocked acid-induced ICSS depression by the end of the 7-day treatment. Acid-induced depression of ICSS and body weight were not blocked by the kappa opioid receptor (KOR) agonist U69593 or the KOR antagonist norbinaltorphimine.
These results support effectiveness of bupropion to alleviate signs of pain-related behavioral depression in rats and further suggest that nortriptyline and citalopram produce significant but less reliable effects.
多巴胺(DA)、去甲肾上腺素(NE)和 5-羟色胺(5-HT)的突触神经传递主要通过 DA、NE 和 5-HT 转运体(分别为 DAT/NET/SERT)重新摄取到突触前末端而终止。单胺转运体抑制剂构成了一类用于治疗抑郁症和疼痛的药物,这些化合物的治疗效果通常需要重复治疗数天或数周。
本研究比较了单胺转运体抑制剂在与疼痛相关的正强化操作性反应抑郁的临床前疼痛模型中重复治疗产生的镇痛作用。
成年 Sprague-Dawley 大鼠配备了针对大脑奖励区域的微电极,以在颅内自我刺激(ICSS)程序中响应电脑刺激脉冲。腹腔注射稀乳酸作为有害刺激,可反复抑制 ICSS,并在重复酸给药的 7 天内导致体重减轻。
非甾体抗炎药酮咯酸的重复预处理完全阻断了酸诱导的 ICSS 和体重下降。DAT 选择性抑制剂安非他酮也完全阻断了酸诱导的 ICSS 抑制和体重减轻,整个 7 天的治疗期间均如此。NET 选择性抑制剂去甲替林和 SERT 选择性抑制剂西酞普兰的效果通常较差,但这两种药物在 7 天治疗结束时均阻断了酸诱导的 ICSS 抑制。κ 阿片受体(KOR)激动剂 U69593 或 KOR 拮抗剂 norbinaltorphimine 均未阻断酸诱导的 ICSS 抑制和体重减轻。
这些结果支持安非他酮缓解大鼠与疼痛相关的行为性抑郁迹象的有效性,并进一步表明去甲替林和西酞普兰产生了显著但不太可靠的效果。